These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17720889)

  • 1. New pharmacologic approaches to treating diabetic retinopathy.
    Ryan GJ
    Am J Health Syst Pharm; 2007 Sep; 64(17 Suppl 12):S15-21. PubMed ID: 17720889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-invasive, multi-target approach to treat diabetic retinopathy.
    Julius A; Hopper W
    Biomed Pharmacother; 2019 Jan; 109():708-715. PubMed ID: 30551523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    ; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruboxistaurin: LY 333531.
    Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for and managing diabetic retinopathy: current approaches.
    Bloomgarden ZT
    Am J Health Syst Pharm; 2007 Sep; 64(17 Suppl 12):S8-14. PubMed ID: 17720893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of PKC beta in diabetic retinopathy and macular edema.
    Aiello LP
    Surv Ophthalmol; 2002 Dec; 47 Suppl 2():S263-9. PubMed ID: 12507628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral targeting of protein kinase C receptor: promising route for diabetic retinopathy?
    Pathak D; Gupta A; Kamble B; Kuppusamy G; Suresh B
    Curr Drug Deliv; 2012 Jul; 9(4):405-13. PubMed ID: 22520069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the treatment of diabetic retinopathy.
    Yam JC; Kwok AK
    Hong Kong Med J; 2007 Feb; 13(1):46-60. PubMed ID: 17277392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 21st Century treatment of diabetic retinopathy.
    Chibber R; Chibber S; Kohner EM
    Expert Rev Endocrinol Metab; 2007 Sep; 2(5):623-631. PubMed ID: 30736125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.
    Frank RN
    Am J Ophthalmol; 2002 May; 133(5):693-8. PubMed ID: 11992868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for diabetic retinopathy.
    Pipis A; Scholl S; Augustin AJ
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):669-81. PubMed ID: 22112046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological approach to diabetic retinopathy.
    De La Cruz JP; González-Correa JA; Guerrero A; de la Cuesta FS
    Diabetes Metab Res Rev; 2004; 20(2):91-113. PubMed ID: 15037985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.
    Hernández C; Simó R
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1209-26. PubMed ID: 17685870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.